Eric H. Oshita

Eric H. Oshita serves as a key procurement specialist within W40M Mrco Pacific, supporting the Department of the Army’s mission to sustain advanced medical readiness across the Indo-Pacific theater. In his secondary role, he facilitates the acquisition of critical biomedical and electromedical infrastructure, with a primary focus on in-vitro diagnostic systems, surgical instrumentation, and clinical laboratory equipment. His responsibilities include coordinating contract execution, ensuring compliance with federal procurement regulations, and aligning acquisitions with operational needs of military treatment facilities. Oshita’s work directly enables the deployment of cutting-edge diagnostic capabilities to forward-deployed medical units, ensuring force health protection and mission continuity in austere environments. Oshita maintains consistent working relationships with leading biomedical suppliers including Roche Diagnostics Corporation, BioFire Defense LLC, Siemens Healthcare Diagnostics Inc., Jupiter Logix Inc., and Kundo Enterprise Co., Ltd. These partnerships center on the procurement of high-complexity diagnostic platforms, molecular detection systems, and electromedical devices certified for military use. His contracting patterns reflect a preference for established industry leaders with proven track records in defense-grade product reliability, regulatory compliance, and rapid logistics support. These vendor relationships are characterized by long-term contract performance, technical collaboration, and adherence to stringent military specifications. Oshita’s procurement portfolio exhibits no set-aside preferences, with 100% of awards issued under full and open competition. This reflects a strategic emphasis on technical capability and operational readiness over socioeconomic categorization, prioritizing mission-critical performance and supply chain resilience. While small business participation is not formally incentivized in his acquisitions, all procurements remain compliant with federal transparency and fair competition standards. His primary focus is on NAICS 325413, In-Vitro Diagnostic Substance Manufacturing, encompassing the acquisition of reagents, automated analyzers, point-of-care testing systems, and associated consumables. Oshita’s expertise lies in procuring FDA-cleared and military-qualified diagnostic technologies that support infectious disease surveillance, blood screening, and battlefield triage, ensuring medical units are equipped with the most reliable, deployable diagnostic tools available.